Evidence map›Paper›PMID 37366796›Full record

ReviewBiotech (Basel (Switzerland))2023

Ocular-Surface Regeneration Therapies for Eye Disorders: The State of the Art.

Matteo Posarelli, Davide Romano, Davide Tucci, Giuseppe Giannaccare, Vincenzo Scorcia, Andrea Taloni, Luca Pagano, Alfredo Borgia

Open access · goldAbstract readReview
In one paragraph

Review in Biotech (Basel (Switzerland)), 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. [Limbal diseases].Die Ophthalmologie · 2026
    Review
  3. Article
  4. Review
  5. Article
  6. Review
  7. Article
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors at 5 institutions in 2 countries.

Matteo PosarelliSt. Paul's Eye Unit, Department of Corneal Diseases, Royal Liverpool University Hospital, Liverpool L7 8YE, UK.
Davide RomanoEye Clinic, Department of Neurological and Vision Sciences, University of Brescia, 25123 Brescia, Italy.ORCID 0000-0002-8961-242X
Davide TucciDepartment of Biomedical and Surgical Sciences, Section of Ophthalmology, S. Maria Della Misericordia Hospital, University of Perugia, 06123 Perugia, Italy.
Giuseppe GiannaccareDepartment of Ophthalmology, University Magna Græcia of Catanzaro, 88100 Catanzaro, Italy.ORCID 0000-0003-2617-0289
Vincenzo ScorciaDepartment of Ophthalmology, University Magna Græcia of Catanzaro, 88100 Catanzaro, Italy.ORCID 0000-0001-6826-7957
Andrea TaloniDepartment of Ophthalmology, University Magna Græcia of Catanzaro, 88100 Catanzaro, Italy.
Luca PaganoSt. Paul's Eye Unit, Department of Corneal Diseases, Royal Liverpool University Hospital, Liverpool L7 8YE, UK.ORCID 0000-0001-8534-6817
Alfredo BorgiaSt. Paul's Eye Unit, Department of Corneal Diseases, Royal Liverpool University Hospital, Liverpool L7 8YE, UK.ORCID 0000-0002-3976-242X
Magna Graecia University · ITUniversity of Liverpool · GBUniversity Hospitals of Leicester NHS Trust · GBUniversity of Perugia · ITUniversity of Siena · IT

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The ocular surface is a complex structure that includes cornea, conjunctiva, limbus, and tear film, and is critical for maintaining visual function. When the ocular-surface integrity is altered by a disease, conventional therapies usually rely on topical drops or tissue replacement with more invasive procedures, such as corneal transplants. However, in the last years, regeneration therapies have emerged as a promising approach to repair the damaged ocular surface by stimulating cell proliferation and restoring the eye homeostasis and function. This article reviews the different strategies employed in ocular-surface regeneration, including cell-based therapies, growth-factor-based therapies, and tissue-engineering approaches. Dry eye and neurotrophic keratopathy diseases can be treated with nerve-growth factors to stimulate the limbal stem-cell proliferation and the corneal nerve regeneration, whereas conjunctival autograft or amniotic membrane are used in subjects with corneal limbus dysfunction, such as limbal stem-cell deficiency or pterygium. Further, new therapies are available for patients with corneal endothelium diseases to promote the expansion and migration of cells without the need of corneal keratoplasty. Finally, gene therapy is a promising new frontier of regeneration medicine that can modify the gene expression and, potentially, restore the corneal transparency by reducing fibrosis and neovascularization, as well as by stimulating stem-cell proliferation and tissue regeneration.

Indexed as

amniotic membraneautologous serum teardry-eye diseaselimbal stem cellsneurotrophic keratopathyocular-surface diseasetissue regeneration

Identifiers

PMID37366796
PMCPMC10295950
OpenAlexW4380988621

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.